A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT02740985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination in Patients With Advanced Solid Malignancies
Study identification
- NCT ID
- NCT02740985
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 313 participants
Conditions and interventions
Conditions
Interventions
- AZD4635 Drug
- Abiraterone Acetate Drug
- Docetaxel Drug
- Durvalumab Drug
- Enzalutamide Drug
- Oleclumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2016
- Primary completion
- Dec 30, 2020
- Completion
- Mar 30, 2023
- Last update posted
- May 25, 2023
2016 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fayetteville | Arkansas | 72703 | — |
| Research Site | Fresno | California | 93720 | — |
| Research Site | Denver | Colorado | 80218 | — |
| Research Site | New Haven | Connecticut | 06519 | — |
| Research Site | Daytona Beach | Florida | 32117 | — |
| Research Site | Lecanto | Florida | 34461 | — |
| Research Site | North Port | Florida | 34288 | — |
| Research Site | Sarasota | Florida | 34232 | — |
| Research Site | Decatur | Illinois | 62526 | — |
| Research Site | Las Vegas | Nevada | 89119 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02740985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02740985 live on ClinicalTrials.gov.